Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.
about
Recent advances in the management of Hodgkin lymphomaInfectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapyCost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaT-cell Lymphoma Epidemiology: the Known and Unknown.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.FDG-PET Scan: a new Paradigm for Follicular Lymphoma ManagementEmergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research NetworkAssociation between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 studyDetection and Identification of Hematologic Malignancies and Solid Tumors by an Electrochemical Technique.Genome-wide homozygosity signature and risk of Hodgkin lymphoma.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesRisk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma.Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.2016 US lymphoid malignancy statistics by World Health Organization subtypes.Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.Cancer in adolescents and young adults living with HIV.The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up.Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.Palliative care specialists' perceptions concerning referral of haematology patients to their services: findings from a qualitative study.Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma.Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.Myeloma: Patient accounts of their pathways to diagnosis.Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases.Cohort Profile: The Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort.Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.Gastric follicular lymphoma: A report of 3 cases and a review of the literature.MicroRNAs as Biomarkers of B-cell LymphomaLong-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysisDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
P2860
Q26751214-7B8B52F5-2A32-48BD-9472-4A161A31B524Q26770344-1C81B90C-2DFA-465D-9B8A-8AFB719EEE43Q26779612-281CEF9F-56D9-4D84-AB63-FC5606354F34Q30239985-98DBE214-3BB9-478E-902D-17E479E936A3Q30240133-6D919CDC-5655-4B5A-BB5E-45890C99493BQ31111112-DB37D15D-3477-4A8D-9E43-6C8B16BC885BQ33628746-7DF03DC8-16B4-4A48-AFC9-AEE5C7699AC6Q33642244-834BE0B6-482E-4731-B6BA-DF9DEC5C210CQ33732402-E02F8EB3-3E43-4564-A0EA-999B363F1E44Q33816002-FE93E058-FE3F-4343-9C0A-81C07B93C5E3Q35999322-A85C00BB-3A45-4F74-BEDB-1D929D265B1BQ36099366-4DE7C53D-CFED-4312-986F-CD60276952F4Q36278006-D24420E4-2B17-4A93-927B-77FC51E9A5E8Q36295008-8F24BB27-A8DD-407B-AD8E-7733732AAE83Q37120684-15E9D1F3-FF87-48D1-978A-0A8939552BCBQ38600671-BDECEF96-51EF-4E2D-8BCB-EF641A875390Q38612385-BF9CD3AF-A991-4654-8782-8075A4D6D96FQ39400737-93470B5A-1651-4A81-A6C8-BBB1B7443E5EQ39914674-B33368E0-A7D7-4783-8348-6B77764B9FC0Q39938060-5A75BB10-FB08-4555-95BF-58B7585115AAQ47125417-6243419E-F1A0-4C64-A4C7-940229470CBDQ47663945-F3585AD7-9575-4310-AF90-72E2C8AD4DECQ49814417-A604FEDC-81C6-4B9F-9397-2809B0D2EB07Q50090795-A59B6F35-5F63-4317-AACE-20A4A7D67F2BQ50271165-670DD7FF-72C9-4C11-8584-F0A1EAF6F152Q50298267-0A7EB7FF-479F-4094-879B-F7F82EA841DEQ50794996-67EB235B-4E73-4871-A32A-5265EEF3A98CQ50976585-A99406C9-02A9-4AB0-9117-CFCBC78E395EQ52607534-91B42BEC-8A2F-4454-9C71-F85A9B7AE60DQ52658547-2266E8FF-F355-4DF7-8BD6-4F86DD5E7695Q52685422-BE293B22-50CD-4297-89FB-58162E7A8A12Q52802234-3C2F225A-5179-45AF-87E2-24E58A3D32C1Q52869166-800E4002-2E69-4FFA-AFA3-BB737FFB36A6Q54151779-8D2D3BB5-018A-4B18-8B31-EA9638573A38Q55399855-B33BAFF7-8B4C-4BCB-BE47-BC9545066166Q57814100-36A07986-D0A3-43D0-94AC-00030B3B5BE1Q58775872-F18CB247-AB59-4A0B-877B-274D372416A2Q58794709-D0ECCB3B-256D-44A6-9F8E-CDE06C93E119
P2860
Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@ast
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en-gb
type
label
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@ast
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en-gb
prefLabel
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@ast
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en-gb
P2093
P2860
P356
P1476
Lymphoma incidence, survival a ...... l Malignancy Research Network.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2015.94
P407
P577
2015-03-24T00:00:00Z
P5875
P6179
1009556116